[...] GLP-1 drugs offer non-surgical weight loss, while bariatric surgery provides lasting metabolic changeswe break down which option suits different needs
Stawarczyk D, Majerus S, Maj M, Van der Linden M, D'Argembeau A
Therefore, blood glucose levels in these patients should be kept under regular control during treatment
Move Forward With Confidence With provider-guided care and continued monitoring, patients receive ongoing support throughout treatment
It comes within the group of medications known as GLP-1 protein activators
A 1:1 matching on propensity score ( 0.02) of subjects treated with ALCAR 3 g/day with not treated subjects, and, separately, of subjects treated with ALCAR 1.5 g/day with not treated subjects, was then performed using the same pool of not treated subjects